for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

Johnson & Johnson

JNJ.N

Latest Trade

148.40USD

Change

1.18(+0.80%)

Volume

1,158,652

Today's Range

147.82

 - 

149.25

52 Week Range

109.17

 - 

157.00

As of on the New York Stock Exchange ∙ Minimum 15 minute delay

Pricing

Previous Close
147.22
Open
149.10
Volume
1,158,652
3M AVG Volume
145.11
Today's High
149.25
Today's Low
147.82
52 Week High
157.00
52 Week Low
109.17
Shares Out (MIL)
2,632.82
Market Cap (MIL)
387,604.30
Forward P/E
18.71
Dividend (Yield %)
2.74

Next Event

Dividend For JNJ.N - 1.0100 USD

Latest Developments

More

J&J Announces Agreement With U.S. Government For 100 Mln Doses Of Investigational Covid-19 Vaccine

Janssen Announces Health Canada Approval Of Darzalex Subcutaneous Formulation For Multiple Myeloma

Janssen Announces U.S. FDA Approval of Spravato CIII Nasal Spray

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

About Johnson & Johnson

Johnson & Johnson is a holding company, which is engaged in the research and development, manufacture and sale of a range of products in the healthcare field. It operates through three segments: Consumer, Pharmaceutical and Medical Devices. Its primary focus is products related to human health and well-being. The Consumer segment includes a range of products used in the baby care, oral care, skin care, over-the-counter pharmaceutical, women's health and wound care markets. The Pharmaceutical segment is focused on five therapeutic areas, including immunology, infectious diseases, neuroscience, oncology, and cardiovascular and metabolic diseases. The Medical Devices segment includes a range of products used in the orthopedic, surgery, cardiovascular, diabetes care and vision care fields. Its research facilities are located in the United States, Belgium, Brazil, Canada, China, France, Germany, India, Israel, Japan, the Netherlands, Singapore, Switzerland and the United Kingdom.

Industry

Biotechnology & Drugs

Contact Info

1 Johnson And Johnson Plz

NEW BRUNSWICK, NJ

08933-0001

United States

+1.732.5242455

https://www.jnj.com/

Executive Leadership

Alex Gorsky

Chairman of the Board, Chief Executive Officer

Paulus A. Stoffels

Vice Chairman- Executive Committee, Chief Scientific Officer

Joaquin Boix Duato

Vice Chairman - Executive Committee

Joseph J. Wolk

Chief Financial Officer, Executive Vice President

Peter M. Fasolo

Chief Human Resource Officer, Executive Vice President

Key Stats

1.95 mean rating - 19 analysts
Sell
Hold
Buy
Revenue (MM, USD)

2017

76.5K

2018

81.6K

2019

82.1K

2020(E)

80.6K
EPS (USD)

2017

7.300

2018

8.180

2019

8.680

2020(E)

7.867
Price To Earnings (TTM)
26.41
Price To Sales (TTM)
4.81
Price To Book (MRQ)
6.15
Price To Cash Flow (TTM)
17.70
Total Debt To Equity (MRQ)
48.26
LT Debt To Equity (MRQ)
39.79
Return on Investment (TTM)
12.13
Return on Equity (TTM)
9.50

Latest News

Latest News

U.S. to pay $1 billion for 100 million doses of Johnson & Johnson's COVID-19 vaccine candidate

The United States government will pay Johnson & Johnson <JNJ.N> over $1 billion for 100 million doses of its potential coronavirus vaccine, as it stocks up on vaccine and drugs in an attempt to tame the pandemic.

Johnson & Johnson starts human study of COVID-19 vaccine after promising monkey data

Johnson & Johnson <JNJ.N> on Thursday kicked off U.S. human safety trials for its COVID-19 vaccine after releasing details of a study in monkeys that showed its best-performing vaccine candidate offered strong protection in a single dose.

FACTBOX- The race for a coronavirus vaccine

(Adds Osaka University, Kentucky Bioprocessing, Vaxine, Medigen; Updates CureVac, J&J, GSK) July 29 (Reuters) - More than 150 vaccines are being developed and tested around the world to stop the COVID-19 pandemic, with 25 in human clinical trials, according to the World...

Exclusive: J&J in talks with Japan, Gates Foundation to lock in deals on COVID-19 vaccine

Johnson & Johnson is in talks with the government of Japan and the Bill and Melinda Gates Foundation about locking up allocations of its potential COVID-19 vaccine as it prepares to kick off human trials, the company's Chief Financial Officer Joseph Wolk told Reuters in...

EXCLUSIVE-J&J says in talks with Japan, Gates Foundation to lock in deals on COVID-19 vaccine

Johnson & Johnson is in talks with the government of Japan and the Bill and Melinda Gates Foundation about locking up allocations of its potential COVID-19 vaccine in advance of it producing any of the medicines, the company's Chief Financial Officer Joseph Wolk told Reuters...

J&J says large study of coronavirus vaccine could begin in September

Johnson & Johnson said on Thursday it is aiming to begin in September a late-stage study of its experimental vaccine for the novel coronavirus, as researchers work at break-neck speed to develop a shot to combat the fast-spreading pathogen.

J&J eyes September for late-stage study of potential COVID-19 vaccine

Johnson & Johnson said on Thursday it was in talks to begin late-stage studies of its experimental coronavirus vaccine in September.

UPDATE 2-J&J raises forecast after quarterly profit beats estimates

Johnson & Johnson raised its full-year profit forecast and beat analysts' estimates for quarterly earnings on Thursday as strength in its pharmaceuticals unit cushioned a steep fall in sales of its medical devices due to the COVID-19 pandemic.

Johnson & Johnson profit tumbles 35% as COVID-19 slams medical device sales

Johnson & Johnson reported a 35.3% fall in second-quarter profit on Thursday as demand for its medical devices was hammered by hospitals putting off non-urgent procedures such as knee and hip replacement due to the COVID-19 pandemic.

Johnson & Johnson's Cilag to sell up to 11.8 million Idorsia shares

Johnson & Johnson's <JNJ.N> Cilag Holding will offer up to approximately 11.8 million existing ordinary shares in Idorsia Ltd <IDIA.S> in an accelerated bookbuilding to commence on Wednesday, the transaction's bookrunner said.

Nonprofits urge Johnson & Johnson to halt sales of Baby Powder globally

More than 170 nonprofit groups on Wednesday called for Johnson & Johnson <JNJ.N> to stop selling its talc-based Johnson’s Baby Powder world-wide, citing concerns that it contains cancer-causing asbestos, according to a statement from advocacy group Black Women for Wellness.

Johnson & Johnson cuts price of TB drug bedaquiline in poorer countries

Johnson & Johnson <JNJ.N> said on Monday it was slashing the price of its version of tuberculosis drug bedaquiline to $340 from $400, for a six-month treatment, in low- and middle-income countries, to scale up its use during the COVID-19 pandemic.

Johnson & Johnson cuts price of TB drug bedaquiline in poorer countries

Johnson & Johnson said on Monday it was slashing the price of its version of the tuberculosis drug bedaquiline to $340 from its original price of $400, for a six-month treatment, in low- and middle-income countries, to scale up its use during the COVID-19 pandemic.

BRIEF-J&J Says Will Make Bedaquiline Available To Stop TB Partnership’s Global Drug Facility At $340 Per Six-Month Treatment Course

* J&J - EFFECTIVE IMMEDIATELY, CO WILL MAKE BEDAQUILINE AVAILABLE TO STOP TB PARTNERSHIP’S GLOBAL DRUG FACILITY AT $340 PER SIX-MONTH TREATMENT COURSE

Emergent signs five-year deal backing J&J COVID-19 vaccine

Emergent BioSolutions Inc <EBS.N> said on Monday it signed a five-year contract to make the drug substance used in Johnson & Johnson's <JNJ.N> COVID-19 vaccine candidate, adding to a series of deals likely to put it at the heart of future global vaccine production.

BRIEF-Emergent Biosolutions Says Will Begin Providing Large-Scale Drug Substance Manufacturing For Johnson & Johnson's Adenovirus-Based Covid-19 Vaccine In 2021

* EMERGENT BIOSOLUTIONS SIGNS FIVE-YEAR AGREEMENT FOR LARGE-SCALE DRUG SUBSTANCE MANUFACTURING FOR JOHNSON & JOHNSON’S LEAD COVID-19 VACCINE CANDIDATE

Emergent to make drug substance for J&J's COVID-19 vaccine candidate

Emergent BioSolutions Inc said on Monday it has signed a five-year pact to make the drug substance used in Johnson & Johnson's COVID-19 vaccine candidate, in a deal valued at about $480 million for the first two years.

J&J scraps late-stage study testing Stelara for lupus

Johnson & Johnson's Janssen unit said on Friday it would discontinue a late-stage study testing its psoriatic arthritis drug Stelara as a treatment for lupus as it was not found to be effective against the auto-immune disease.

J&J scraps late-stage study testing Stelara for lupus

Johnson & Johnson's Janssen unit said on Friday it would discontinue a late-stage study testing its psoriatic arthritis drug Stelara as a treatment for lupus due to lack of efficacy.

J&J loses bid to overturn baby powder verdict, but damages cut to $2.12 billion

A Missouri appeals court on Tuesday rejected Johnson & Johnson's bid to throw out a jury verdict in favor of women who blamed their ovarian cancer on its baby powder and other talc products, but reduced damages by more than half, to $2.12 billion.

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up